Sentences with phrase «tumor model of»

«Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2 - targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel.»

In this study, we explored the antitumor potential of prostate stem cell antigen (PSCA)- redirected CAR T and mucin 1 (MUC1)- redirected CAR T cells in tumor models of NSCLC.

Not exact matches

Capsaicin additionally produced a significant deceleration of the development of prostate tumors created simply by those human cell lines grown in mouse models.

«We also confirmed a role in PDAC tumor maintenance as inhibition of PRMT1 in patient - derived mouse models significantly inhibited tumor growth and extended survival,» said Giuliani.

In December 2017, writing in Computer Methods in Applied Mechanics and Engineering, Yankeelov and collaborators at UT Austin and Technical University of Munich, showed that they can predict how brain tumors (gliomas) will grow and respond to X-ray radiation therapy with much greater accuracy than previous models.

In October 2016, writing in Mathematical Models and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therModels and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various thermodels to determine which could predict key quantities of interest relevant to survival, and the effects of various therapies.

Model of tumor growth in a rat brain before radiation treatment (left) and after one session of radiotherapy (right).

Over the years, many different mathematical models of tumor growth have been proposed, but determining which is most accurate at predicting cancer progression is a challenge.

«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.

According to ICES Director J. Tinsley Oden, mathematical models of the invasion and growth of tumors in living tissue have been «smoldering in the literature for a decade,» and in the last few years, significant advances have been made.

They implemented this principle through the development and application of something they call the «Occam Plausibility Algorithm,» which selects the most plausible model for a given dataset and determines if the model is a valid tool for predicting tumor growth and morphology.

«This approach will hopefully lead to better mechanistic predictive modeling of response and future design of therapies that further take advantage of how the immune system recognizes tumors.»

PDX models are created by implanting cancerous tissue from a human primary tumor directly into immunodeficient mouse or rat models, enabling acceleration of oncology research or drug discovery and development programs.

A raft of studies in laboratory animals, molecular models and cancer patients suggest that pain drugs given during and after cancer surgery stimulate the growth and spread of certain tumors.

The researchers then induced melanoma tumors in their model and evaluated the effects of a battery of immunotherapies.

«Particularly in such patients with underlying CKD, our modeling results support the integration of renal tumor anatomic features at cross-sectional imaging into decision making for treatment of small renal masses and may be used to provide a patient - centered framework for selection of optimal candidates for ablative therapy,» Kang said.

«This model was trained on genetic data from human tumors in The Cancer Genome Atlas and was able to predict response to certain inhibitors that affect cancers with overactive Ras signaling in an encyclopedia of cancer cell lines,» Greene said.

Traditional genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be profiled for their ability to selectively kill cells in a molecular context that matches those found in tumors.

In this new study published in Nature, Alexandra Van Keymeulen and colleagues used state of the art genetic mouse models to identify the cellular origin of PIK3CA and p53 induced breast tumors.

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

«Lower - carb diet slows growth of aggressive brain tumor in mouse models.»

«We know that 70 - 75 percent of glioblastoma patients undergo surgery for tumor debulking, and we have previously shown that MSCs encapsulated in biocompatible gels can be used as therapeutic agents in a mouse model that mimics this debulking,» he continued.

«It's very difficult to produce a mouse model of a solid tumor of the type we see in most women who are diagnosed with cervical cancer.

Again, using mouse models of glioblastoma — this time created from brain tumor cells that were resistant to the herpes virus — the therapy led to increased animal survival.

For this study, Guttridge, first author David J. Wang, who developed many of the study's concepts, and their colleagues monitored NF - kB activity during tumor development using mouse embryonic fibroblasts and two mouse models.

Moreover, experiments on an ovarian cancer murine model that investigated the effects of orally administered ONA resulted in longer lifespans and inhibited ovarian cancer tumor development.

Testing each of these factors for their ability to return differentiated tumor cells to a stem - like state, identified a combination of four — POU3F2, SOX2, SALL2 and OLIG2 — that was able to reprogram differentiated tumor cells back into glioblastoma stem cells, both in vitro and in an animal model.

Engineered human immune cells can vanquish a deadly pediatric brain tumor in a mouse model, a study from the Stanford University School of Medicine has demonstrated.

This treatment prevented the formation of polyps, showing that bacteria are essential for early tumor development in this model.

The researchers confirmed these findings in a mammary carcinoma mouse model — treatment with dasatinib just a few days after administering two high doses of chemotherapy prevented tumor growth and increased survival rates.

The researchers took this discovery and, in an animal model, identified a drug that is able to re-activate those immune cells and reduce brain tumor growth, thereby increasing the lifespan of mice two to three times.

The next step for the researchers is to demonstrate the viability of this approach to the production and delivery of an anticancer molecule in a whole tumor model system.

Kilian said his team's synthetic microenvironment lies somewhere in the middle of two extremes in the field of modeling biology: the hard plastic plate, and expensive mouse avatars that are created by injecting human tumor cells into mice.

Kuang is also involved in efforts to model various aspects of tumor growth and management as part of ASU's efforts on cancer research.

Weeraratna's team used an artificial skin reconstruct model to recreate the interactions of melanoma cells with either a young or aged tumor microenvironment.

He and his co-investigators analyzed 66 ultrasound images of tumors (32 pictures of a single tumor and 34 of multiple tumors) inside a plastic model of a breast to determine the augmented - reality system's accuracy of measuring tumor volume.

BPTES has been used in animal models for a variety of cancers but has not substantially reduced tumor sizes, probably because the drug concentration in tumor tissue is not high enough when using conventional drug formulation methods, say the scientists.

One form of pancreatic cancer has a new enemy: a two - drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

Last fall, Bergö's group reported that ingestion of extra antioxidants drove the metastasis of melanoma in a mouse model, though they didn't have any effect on the primary tumor.

«Despite the low infection levels of mouse cells with oHSV, we were able to cause a delay in tumor growth in one of the cancer models and even cure many of the mice in a second model,» said first author Jennifer Leddon, who conducted much of the laboratory work during a research experience in the Center for Childhood Cancer and Blood Diseases.

Its research includes a cluster of related interdisciplinary projects that examine disparities in breast cancer mortality between African - American and Caucasian women using animal models, molecular characterization of tumors, and behavioral research focused on social - environmental factors.

In the current study, Dr. Xu and colleagues gave radiation therapy to a mouse model of human pancreatic cancer to eradicate the bulk tumors, while only the cancer stem cells remained in the residual scars.

«The effective immune response didn't happen in every tumor model we tested, so we still need to figure out exactly what triggered the tumor shrinkage and how to predict which tumors will shrink in response to virotherapy,» said Leddon, who is also working toward her medical and doctoral degrees at the University of Cincinnati.

In collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surface.

In a mouse model of triple - negative breast cancer, mice injected with cancer cells that over-express ZMYND11 had tumor volumes of less than 50 cubic millimeters while control mice and those injected with cells expressing ZMYND11 deficient for binding to the methyl group had tumor volumes ranging from 150 to 400 cubic millimeters at eight weeks.

Previous work on cartilage tumors has been done using models based on genetic mutations that occurred only rarely in enchondromas; however, IDH mutations are present in a high percentage of enchondromas.

Desgrosellier said the team will follow up with mouse models containing tumor fragments from patients to better reflect the diversity of cell types present in human disease.

A team of researchers, led by Ross Cagan, PhD, developed a multi-gene lung cancer model in the fruit fly Drosophila to better understand the mechanisms that promote tumors in NSCLC.

The mouse model could also contribute to the further development of immunotherapies — a method in which the body's immune system is stimulated, so that it intensifies its fight against tumor cells.

However, when the researchers switched on KRAS in the preclinical models, an entirely different kind of tumor formed, called angiosarcoma.